Across 12 systematic reviews, SGLT2 inhibitors lowered the composite of cardiovascular death or first heart-failure hospitalisation (HR 0.77), major adverse cardiovascular events (HR 0.91) and kidney disease progression (RR 0.63). Liver fat fell by 2.05 percentage points on imaging, and a randomised-trial subgroup showed fewer gout events (HR 0.74). Genital infections rose more than threefold (RR 3.30), while urinary tract infection and ketoacidosis signals were imprecise. COVID-19 mortality was not clearly reduced. Every included review earned critically low AMSTAR-2 confidence.
The cardiorenal findings echo what large trials such as EMPA-REG, DAPA-HF, DAPA-CKD and EMPA-KIDNEY have already shown, so this is confirmatory rather than paradigm-shifting. The useful contribution is the restraint: the authors resist the "miracle drug" framing. Heart and kidney benefits hold in heart-failure and chronic kidney disease populations, including people without diabetes, and that matters for adults weighing these drugs for organ protection. The liver result is an imaging measure, mostly in people with type 2 diabetes, so it says little about hard liver outcomes. The gout signal rests on a modest subgroup with a confidence interval brushing 1.0. The critically low review quality, retrospective registration and PubMed-only search all warrant caution, and overlapping trials across reviews mean the estimates are not independent. Anyone considering an SGLT2 inhibitor should discuss it with a physician, particularly given the roughly threefold genital infection risk.